)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Kronos Bio
Kronos Bio (KRON) investor relations material
Kronos Bio has been acquired
Kronos Bio Q1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2025 earnings summary8 May, 2025
Executive summary
Discontinued lead clinical program (istisociclib) in November 2024 due to adverse events and unfavorable benefit-risk profile; initiated strategic review for alternatives including merger or dissolution.
Entered into a Merger Agreement with Concentra Biosciences on May 1, 2025; transaction expected to close mid-2025, with a $1.4M termination fee if not completed.
Workforce reduced by 83% as part of three restructuring plans; as of May 2025, only 8 full-time employees remain.
All obligations under the Genentech collaboration were terminated in December 2024; all performance obligations satisfied as of March 31, 2025.
Financial highlights
Revenue for Q1 2025 was $1.9M, down from $2.5M in Q1 2024, all from the Genentech collaboration.
Net loss for Q1 2025 was $8.4M, a significant improvement from $30.0M in Q1 2024.
Research and development expenses dropped to $2.1M in Q1 2025 from $14.2M in Q1 2024, reflecting program discontinuation and restructuring.
General and administrative expenses were $6.1M in Q1 2025, down from $7.5M in Q1 2024.
Cash, cash equivalents, and investments totaled $99.7M as of March 31, 2025.
Outlook and guidance
Cash and investments expected to fund operations for at least 12 months from March 31, 2025.
If the merger is not completed, the board may pursue dissolution and liquidation.
Pending merger restricts business activities and capital allocation; significant transaction costs expected regardless of outcome.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Kronos Bio
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Kronos Bio Inc. is a U.S.-based biotechnology company focused on the discovery and development of therapies for cancer and other serious diseases. The company specializes in targeting dysregulated transcription factors and other key regulatory proteins involved in disease progression. Using its proprietary drug discovery platform, Kronos Bio aims to develop small-molecule therapies that address unmet medical needs. Its research spans early discovery through clinical development. The company is headquartered in San Mateo, California, and its shares are listed on the NASDAQ.